Меню
Набор скоро начнётся NCT07673263

Effects of X Box Kinect 360 in Alzheimer's Disease

Без фазы С лечением Alzheimer s Disease

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: 3D Kinect based game, Conventional therapy group.
Кому может быть актуально
Состояния в реестре: Alzheimer s Disease. Базовые параметры: 50 лет — 85 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Пакистан
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Effect of 3D Kinect Games With Google Cardboard on Motor Control, Cognition, and Quality of Life in Mild to Moderate Alzheimer's Patient

Обзор

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).

Подробное описание

In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level. In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023). Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017). Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe. A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).

Вмешательства

  • Другое 3D Kinect based game
    Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.
  • Другое Conventional therapy group
    The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025). The patients will take 1-2 minutes rest after 5 minutes of activity. Rest periods of 1-2 minutes after every 5 minutes of activity.

Первичные конечные точки

  • Cognition [Срок оценки: Baseline]
  • Cognition [Срок оценки: After 6 week of Intervention]
  • Motor Function [Срок оценки: Baseline]
  • Motor Function [Срок оценки: After 6 week of intervention]
  • Quality of Life (QOL) [Срок оценки: Baseline]
  • Quality Of Life (QOL) [Срок оценки: After 6 weeks of Intervention]

Критерии участия

Критерии включения

  • Alzheimer's disease of age between 50-85 years.
  • Diagnosed AD stage Mild to Moderate.

Критерии исключения

  • Undiagnosed AD patients.
  • Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Поддерживающая терапия

Центры проведения

Пакистан · 1 центр
  • Ziauddin University — Karachi

Публикации

  • Cox KL, Clare L, Cyarto EV, Ellis KA, Etherton-Beer C, Southam J, Ames D, Flicker L, Almeida OP, LoGiudice D, Liew D, Vlaskovsky P, Lautenschlager NT. A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Dec PMID 34511499
  • Cousi C, Igier V, Quintard B. French cross-cultural adaptation and validation of the Quality of Life-Alzheimer's Disease scale in Nursing Homes (QOL-AD NH). Health Qual Life Outcomes. 2021 Sep 15;19(1):219. doi: 10.1186/s12955-021-01853-2. PMID 34526034
  • Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo NJ. Advances in Alzheimer's disease's pharmacological treatment. Front Pharmacol. 2023 Jan 26;14:1101452. doi: 10.3389/fphar.2023.1101452. eCollection 2023. PMID 36817126
  • Chen C, Homma A, Mok VC, Krishnamoorthy E, Alladi S, Meguro K, Abe K, Dominguez J, Marasigan S, Kandiah N, Kim SY, Lee DY, De Silva HA, Yang YH, Pai MC, Senanarong V, Dash A. Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region. J Intern Med. 2016 Oct;280(4):359-74. doi: 10.1111/joim.12495. Epub 2016 Mar 16. PMID 26992016
  • Cezar NOC, Ansai JH, de Andrade LP. Home-based multimodal exercise program in older people with Alzheimer disease: Randomized controlled trial protocol. Physiother Res Int. 2021 Apr;26(2):e1899. doi: 10.1002/pri.1899. Epub 2021 Feb 15. PMID 33586858
  • Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003 Oct;51(10):1451-4. doi: 10.1046/j.1532-5415.2003.51465.x. PMID 14511167
  • 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14. PMID 36918389
  • Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith C. Introducing virtual reality therapy for inpatients with dementia admitted to an acute care hospital: learnings from a pilot to pave the way to a randomized controlled trial. Pilot Feasibility Stud. 2020 Oct 31;6(1):166. doi: 10.1186/s40814-020-00708-9. PMID 33292729

Идентификаторы

NCT: NCT07673263 · 11691225SPREH · 11691225SPREH

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗